| Issue |
BIO Web Conf.
Volume 121, 2024
Global Summit on Life Sciences and Bio-Innovation: From Agriculture to Biomedicine (GLSBIA 2024)
|
|
|---|---|---|
| Article Number | 04010 | |
| Number of page(s) | 5 | |
| Section | Frontiers in Genetics and Microbiological Research | |
| DOI | https://doi.org/10.1051/bioconf/202412104010 | |
| Published online | 22 July 2024 | |
Clinical characteristics of children with hymenolepidosis in Bukhara
Bukhara State Medical Institute, Bukhara, Uzbekistan
* Corresponding author: parviz.feruza83@mail.ru
In 12% of children diagnosed with hymenolepiasis, a mild degree of the disease was observed, in 53% - moderate, and in 35% - severe. Of the clinical signs of the disease, weight loss was detected in 57.1% of children with a mild course, in 40.9% with a moderate course and in 92.5% with a severe course. Growth retardation was observed in 57.1%, 34.4% and 71.1% of children, and pruritus - in 50%, 37.7% and 74.3% of children, respectively. The introduction of the immunocorrective drug immunal into the treatment complex for children diagnosed with hymenolepiasis showed a significant increase in the effectiveness of treatment, which is shown as an important recommendation for use in practical healthcare.
© The Authors, published by EDP Sciences, 2024
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.